The Centers for Medicare & Medicaid Services (CMS) announced in an email the end of reporting flexibility for Hospital Quality Reporting and Value-Based Payment programs.
The blanket Extraordinary Circumstances Exception (ECE), announced March 22, will end July 1 and quality data reporting requirements will resume for six programs:
- the Hospital Inpatient Quality Reporting Program;
- the Hospital Outpatient Quality Reporting Program;
- the Prospective Payment System–Exempt Cancer Hospital Quality Reporting Program;
- the Hospital Value-Based Purchasing Program;
- the Hospital-Acquired Condition Reduction Program; and
- the Hospital Readmissions Reduction Program.
CMS is exploring providers’ concerns about the effect of this flexibility and the COVID-19 public health emergency on quality data. The agency, through a future rule, will address potential changes to how voluntarily reported data from the first two quarters of 2020 are used in these programs.
Hospital leaders still may request an ECE on a case-by-case basis within 90 calendar days of an extraordinary circumstance.
Additional Information on Remdesivir Allocation
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) released a fact sheet outlining the process for hospitals to obtain the investigational drug remdesivir to treat COVID-19.
To receive the funding, hospitals every two weeks — from Monday, July 6, through September — must input data by 8 pm ET on confirmed and suspected COVID-19 cases via TeleTracking. ASPR then will notify state and territorial health departments about their allocations. Health departments will determine how much remdesivir hospitals within each jurisdiction will receive and notify the manufacturer, AmerisourceBergen, which will coordinate biweekly shipments to hospitals. Hospitals will be billed through AmerisourceBergen.
FDA Authorizes Third Flu, COVID-19 Diagnostic Test
The Food and Drug Administration (FDA) on July 3 issued an emergency use authorization (EUA) for the third diagnostic test that detects and differentiates the viruses that cause influenza and COVID-19. The Influenza SARS CoV-2 (Flu SC2) Multiple Assay alleviates the need for multiple samplings and helps conserve personal protective equipment. FDA has updated the Molecular Diagnostic EUA templates with information about these tests.
Visit the America’s Essential Hospitals coronavirus resource page for more information about the outbreak.
Contact Senior Director of Policy Erin O’Malley at firstname.lastname@example.org or 202.585.0127 with questions.